RedHill Biopharma Ltd. Sponsored ADRRedHill Biopharma Ltd. Sponsored ADRRedHill Biopharma Ltd. Sponsored ADR

RedHill Biopharma Ltd. Sponsored ADR

No trades
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪4.61 M‬EUR
‪−8.02 M‬EUR
‪7.81 M‬EUR
‪4.53 M‬
Beta (1Y)
2.62

About RedHill Biopharma Ltd. Sponsored ADR


CEO
Dror Ben-Asher
Headquarters
Tel Aviv
Founded
2009
IPO date
Feb 1, 2011
Identifiers
3
ISIN US7574683014
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Check out other big names from the same industry as 2RH.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Displays a symbol's price movements over previous years to identify recurring trends.